The CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) on 10,061 patients with persistent inflammation following myocardial infarction demonstrated that inhibition of IL-1β reduced the risk of major adverse cardiovascular events by 15%, recurrent myocardial infarction by 24%, and cardiovascular mortality by 10% [143,144]. This evidence concerns the gene IL1B and myocardial infarction.